Perimenopause Palpitations: When They're Hormonal and When to See a Cardiologist

Most perimenopausal women who present with palpitations have been told the same two things: it is anxiety, or it is just hormones. Both can be true. Neither is a workup. The clinical question is not whether estrogen fluctuation can cause ectopic beats, it can and does, but whether the palpitations in front of you belong to the benign hormonal majority or the dangerous structural minority.

The Mechanism

Estrogen is not a reproductive hormone that happens to affect the heart. It is a cardiac electrical stabilizer that also regulates reproduction, and when its levels oscillate, the heart notices.

17beta-estradiol modulates the hERG potassium channel responsible for the rapid delayed rectifier current (IKr), which governs ventricular repolarization. When estrogen acts on hERG, it stabilizes repolarization timing across the cardiac cycle. When estrogen fluctuates, that stabilization becomes intermittent, creating windows of repolarization lability during which ectopic beats are more likely to fire (James 2012, Heart Rhythm). Estrogen also acts on L-type calcium channels and shapes autonomic tone, increasing vagal activity and suppressing sympathetic surges. In perimenopause, these effects become unpredictable. Oscillating estrogen levels shift the autonomic balance toward sympathetic dominance, particularly at night, when vasomotor symptoms disrupt sleep and the normally protective vagal tone of deep sleep is absent (Jankowski 2018, Journal of Clinical Endocrinology and Metabolism). 4 / Promising

The result is a structurally normal heart that becomes electrically irritable. The three common phenotypes:

Premature ventricular contractions (PVCs): felt as a skip followed by a heavy thud. The pause is the PVC; the thud is the post-pause compensatory beat filling a slightly overfilled ventricle.

Premature atrial contractions (PACs): typically described as a flip-flop or a brief hiccup in the chest. Less forceful than PVCs because atrial stroke volume is smaller.

Inappropriate sinus tachycardia: a resting heart rate of 90 to 110 that feels like a low-grade hum or unease, often worse at night after a hot flash, and commonly misread as anxiety.

None of these originate from structural damage. They originate from repolarization lability and autonomic dysregulation on top of a heart that is otherwise working exactly as it should.

What the Evidence Shows

A 2022 scoping review by Hunter and colleagues synthesized 84 studies on menopausal symptoms and found that palpitations cluster reliably with vasomotor symptoms and sleep disruption in midlife women, and that they significantly reduce quality of life even when electrophysiologically benign (Hunter 2022, Menopause). The clustering matters clinically: a woman whose palpitations reliably follow hot flashes and improve after her sleep improves is telling you something about mechanism, not just pattern.

The ion channel work is more precise. James et al. (2012, Heart Rhythm) demonstrated that 17beta-estradiol directly modulates IKr through the hERG channel, with implications for arrhythmia susceptibility across the menstrual cycle and at menopause. Jankowski et al. (2018, Journal of Clinical Endocrinology and Metabolism) established estrogen’s dual role on L-type calcium channels and autonomic tone, providing a mechanistic basis for the sympathetic surge that perimenopausal women often describe as a sudden pounding at 3 a.m. 4 / Promising

On the structural side, the PVC burden literature is the most actionable. Baman et al. (2010, Circulation: Arrhythmia and Electrophysiology) established that PVC burdens above 10 to 15 percent are associated with LV dysfunction that frequently reverses after PVC suppression, defining the intervention threshold. Dukes et al. (2015, Heart Rhythm) confirmed the cardiomyopathy risk at higher burdens and identified wide QRS morphology, epicardial origin, and bigeminy as features that raise risk even at lower burdens. Women may develop PVC-induced cardiomyopathy at lower burdens than men, likely because of smaller baseline LV mass, though sex-specific thresholds have not yet been codified in guidelines. 4 / Promising

For atrial fibrillation, Friberg et al. (2012, New England Journal of Medicine) established that women carry a higher stroke risk per CHA2DS2-VASc point than men, which means that a perimenopausal woman with documented AFib and a score of 1 may need anticoagulation at a threshold where a man with the same score would be observed. 5 / Solid

Thyroid disease is the most common non-cardiac masquerader. Collet et al. (2012, JAMA) demonstrated that subclinical hyperthyroidism (suppressed TSH with normal free T4) increases atrial fibrillation risk two to three times, with a dose-response relationship across the degree of TSH suppression. The discriminator in clinic: thyroid-driven palpitations tend to be persistent sinus tachycardia accompanied by weight loss, heat intolerance, diarrhea, or tremor. Perimenopausal palpitations are episodic ectopics, often nocturnal, without those systemic features.

For monitoring, a 24 to 48 hour Holter has poor diagnostic yield for paroxysmal symptoms because the event may simply not occur in that window. A 7 to 14 day patch monitor or a 30-day event monitor is now the first-line approach for intermittent palpitations and dramatically improves capture rates. When a patient already has wearable data, Apple Watch and KardiaMobile AFib detection have been validated at approximately 98 percent sensitivity for AFib. A documented episode on a consumer device warrants medical evaluation, not dismissal.

Holter thresholds that guide clinical decisions:

PVC burden below 5%: benign in a structurally normal heart. Reassurance, lifestyle optimization, consideration of magnesium or a low-dose beta-blocker if symptoms are disruptive.

PVC burden 5 to 10%: borderline. PVC-induced cardiomyopathy is uncommon but possible, especially with wide QRS (more than 150 ms), epicardial origin, or frequent bigeminy. Repeat echocardiogram at 12 to 24 months. 4 / Promising

PVC burden 10 to 15% and above: intervention threshold. Cardiomyopathy risk rises (Baman 2010, Dukes 2015). Beta-blockers, calcium channel blockers, or catheter ablation are appropriate to discuss. 5 / Solid

PVC burden above 20 to 24%: highest risk group. Ablation is often recommended even if the patient is currently asymptomatic.

For non-sustained ventricular tachycardia (NSVT), defined as 3 or more ventricular beats at 100 bpm or above lasting less than 30 seconds: runs of 3 to 6 beats at 120 to 180 bpm in a structurally normal heart with a normal echo are likely benign. Runs of 8 or more beats, rates above 180 to 200 bpm, onset at rest or during sleep, polymorphic morphology, or any associated presyncope are concerning and require cardiology evaluation.

For pauses: up to 2.0 seconds during sleep is physiologic and common. Pauses of 3.0 seconds or more while awake, or any pause that correlates temporally with syncope, are pathologic and meet criteria for pacing evaluation under current ESC pacing guidelines. 5 / Solid

A note on hormone therapy and palpitations. In women with structurally normal hearts, low atrial fibrillation risk scores, and no history of prior AF, transdermal estradiol at physiologic doses often reduces vasomotor-associated palpitations by stabilizing the autonomic swings that drive ectopy. The mechanism is the same as the one that makes perimenopause arrhythmogenic in the first place: estrogen’s stabilizing effect on IKr and on autonomic tone. Restoring more physiologic estrogen levels through transdermal delivery smooths those oscillations. In women with hypertension, left atrial enlargement on echo, obstructive sleep apnea, or a prior documented episode of AFib, the calculation changes. Estrogen can unmask atrial fibrillation in women who have an underlying substrate. Route matters: oral estrogen undergoes first-pass hepatic metabolism that increases coagulation factors and inflammatory markers; transdermal estradiol bypasses the liver and does not carry the same thrombotic implications. This is not a reason to deny hormone therapy to symptomatic women. It is a reason to discuss it with a cardiologist rather than defaulting to avoidance.

Atrioventricular nodal reentrant tachycardia (AVNRT) is worth naming separately. AVNRT is the most common paroxysmal supraventricular tachycardia in adults, and it is more prevalent in women than men. It presents as a sudden-onset, rapid, regular pounding, often with pulsations in the neck, that terminates abruptly, sometimes spontaneously, sometimes with Valsalva. It is not AFib; it is mechanistically a reentrant circuit within or near the AV node, with a structurally normal heart. It can be highly symptomatic and frightening but is not associated with sudden death in the absence of an accessory pathway. AVNRT is worth identifying because catheter ablation is curative in over 95 percent of cases and carries very low procedural risk. A perimenopausal woman whose palpitations are not driven by hormonal ectopy but by AVNRT is being undertreated if she receives only reassurance.

Congenital Long QT Syndrome in Perimenopausal Women: When Inherited Risk Surfaces at Midlife

Congenital long QT syndrome (LQTS) is a group of inherited ion channel disorders that prolong the cardiac action potential, creating a substrate for torsades de pointes, a potentially fatal polymorphic ventricular tachycardia. The two most common subtypes — LQTS1 (KCNQ1 loss-of-function) and LQTS2 (KCNH2 loss-of-function, the same channel affected by estrogen’s IKr modulation) — show a clinically important sex difference that perimenopause can unmask.

In LQTS2 specifically, women are at higher arrhythmia risk than men across adulthood, while in LQTS1, men predominate before age 15 and women after age 15. Locati and colleagues published a landmark analysis in Circulation in 1998 demonstrating that in LQTS patients overall, women experienced more frequent arrhythmic events in adulthood than men, and the female excess was most pronounced in the third and fourth decade. This reversed the childhood pattern seen in LQTS1, suggesting sex hormone biology is directly modulating arrhythmia penetrance. The mechanism converges on the hERG channel: LQTS2 impairs IKr function, and estrogen’s stabilizing action on hERG means that estrogen partially compensates for the LQTS2 mutation during the reproductive years. When estrogen declines at perimenopause, that partial compensation is removed, and the underlying channelopathy may become symptomatic or more dangerous for the first time.

This has a clinical implication that is not widely recognized: a woman who reaches age 46 to 52 with a previously undiagnosed LQTS2 mutation may have been largely asymptomatic during her reproductive years and present at perimenopause with new palpitations, near-syncope, or frank syncope that is attributed to vasomotor symptoms, anxiety, or vagal episodes. Makkar and colleagues established in JAMA in 1993 that women are substantially more susceptible than men to drug-induced torsades de pointes — an iatrogenic manifestation of acquired QT prolongation that is mechanistically identical to the inherited form.

Any perimenopausal woman presenting with new palpitations accompanied by presyncope, or syncope triggered by auditory stimuli or emotional stress, or a family history of unexplained sudden cardiac death under age 40, warrants QTc measurement on a standard 12-lead ECG. A QTc above 460 milliseconds in a woman is prolonged; above 500 milliseconds warrants cardiology evaluation for inherited channelopathy. The presence of perimenopause is not an explanation for prolonged QTc.

What to Do This Week

1. Apply the OES triad to your own symptoms. Onset (gradual and trigger-linked vs sudden paroxysmal), Exercise response (suppresses with light exertion vs persists or worsens), and Sensation (single thump or 1 to 2 beat flutter vs sustained pounding, chaotic quiver, or pause with dizziness). Hormonal palpitations tend to score in the first column. Structural palpitations tend to score in the second. If any feature is ambiguous, that is a reason to document, not to wait.

2. Know the Plus One rule before your next episode. A palpitation alone is rarely an emergency. A palpitation plus any one of the following changes the picture: fainting or near-fainting, chest pressure radiating to your jaw or left arm, sudden severe shortness of breath, or a rhythm on your wearable that is irregularly irregular in a way you have never seen before. Any Plus One warrants same-day or emergency evaluation, regardless of how many times you have been told it is hormones.

3. Document a wearable rhythm strip if you can. When you feel the palpitation, open the ECG app on your Apple Watch or use a KardiaMobile device. Thirty seconds of rhythm during the event is worth more than 24 hours of monitoring between events. A confirmed AFib trace, even if self-terminating, is a clinical finding.

4. Request a 7 to 14 day patch monitor rather than a 24 to 48 hour Holter. If your physician offers a standard Holter, ask specifically whether your symptoms are frequent enough to be captured in 24 to 48 hours. Paroxysmal palpitations that occur once or twice a week will almost always be missed on a short Holter. Extended monitoring doubles and triples diagnostic yield.

5. Get a TSH with free T4 if you have not had one in the past 12 months. Subclinical hyperthyroidism is common in midlife women, increases AF risk two to three times, and is clinically indistinguishable from perimenopausal ectopy on history alone (Collet 2012, JAMA). It takes one blood draw to exclude it.

Perimenopausal palpitations are common, most are benign, and the ones that are not benign can be identified with the right monitoring at the right duration with the right thresholds applied. Being dismissed is not the same as being cleared. A normal 24-hour Holter in a woman with weekly paroxysmal palpitations is not a negative workup. Know the difference, and ask for the test that can actually answer the question.